SCHEMBL16057906

SCHEMBL16057906

CCCCc1c(-c2ccccc2C)ccnc1OC(=O)O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM5A P29375 2/20 0.38
▸ KDM5B Q9UGL1 2/20 0.38
▸ MCL1 Q07820 2/20 0.38
▸ KDM4C Q9H3R0 1/20 0.38
▸ FFAR1 O14842 2/20 0.36
▸ FFAR4 Q5NUL3 1/20 0.36
▸ MAPT P10636 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ PKM P14618 1/20 0.35
▸ ALOX15 P16050 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ NFKB1 P19838 1/20 0.35
▸ THPO P40225 1/20 0.35
▸ BLM P54132 1/20 0.35
▸ PMP22 Q01453 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16058925 0.84 CYP1A2 (0.40) KDM4CKDM4ELMNACYP1A2TDP1
SCHEMBL16056843 0.81 CYP2C9 (0.44) MAPTKDM4EMEN1LMNACYP1A2
SCHEMBL1838444 0.79 MCL1 (0.43) MCL1FFAR1FFAR4KDM4EMEN1
SCHEMBL16058089 0.79 RARB (0.39) MAPTKDM4EMEN1ALDH1A1LMNA
SCHEMBL16057846 0.78 CCNB2 (0.45) MAPTKDM4EMEN1ALDH1A1CYP1A2
SCHEMBL1839931 0.78 NCEH1 (0.47) MCL1FFAR1FFAR4KDM4EMEN1
SCHEMBL16057516 0.77 TOP2A (0.42) MAPTKDM4EMEN1KMT2A
SCHEMBL1839987 0.75 MCL1 (0.45) MCL1KDM4EMEN1KMT2ANCEH1
SCHEMBL1836011 0.74 PPARA (0.45) MCL1KDM4EMEN1KMT2ANCEH1
SCHEMBL1840439 0.74 PPARA (0.45) MCL1KDM4EMEN1KMT2ANCEH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9828338-B2 Carbamate derivatives of lactam based N-acylethanolamine acid amidase (NAAA) inhibitors THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-11-28 — — US disclosed
US-20160068482-A1 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2016-03-10 — — US disclosed
WO-2014144836-A2 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-09-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160068482-A1 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS NAAA, FAAH, FAAH2 KDM5A 2208/4885KDM5B 2330/4885MCL1 2993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback